Despite first-generation agents (gefitinib and erlotinib) being standard first-line treatments for EGFR-mutant NSCLC, they have been consistently linked to severe, and sometimes fatal, hepatotoxicity [9–13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.